uwa-001 uwa-001 uwa-001 (also known as α-phenyl-mdma and methylenedioxymephenidine) is a phenethylamine derivative invented at the university of western australia as non-toxic alternative to 3,4-methylenedioxy-n-methylamphetamine (mdma) and researched as a potential treatment for parkinson's disease. not to be confused with uwa-101. uwa-001identifiers iupac name 2-(1,3-benzodioxol-5-yl)-n-methyl-1-phenylethanamine cas number1350821-28-1 ypubchem cid17757315chemspider34245583uniizq2r4kpz2wchemblchembl3303514chemical and physical dataformulac16h17no2molar mass255.317 g·mol−13d model (jsmol)interactive image smiles cnc(cc1ccc2ococ2c1)c3ccccc3 inchi inchi=1s/c16h17no2/c1-17-14(13-5-3-2-4-6-13)9-12-7-8-15-16(10-12)19-11-18-15/h2-8,10,14,17h,9,11h2,1h3key:dnotuuouofjqjc-uhfffaoysa-n it has a 5-ht2a receptor affinity of 1.2 μm (∼10-fold increase compared to mdma), 1.3 μm for the serotonin transporter (∼4-fold decrease compared to mdma), 13.4 μm for the norepinephrine transporter (∼26-fold increase compared to mdma) and virtually no affinity for the dopamine transporter (>50 μm). unlike mdma and para-methoxyamphetamine (but similarly to ketamine), uwa-001 increases prepulse inhibition and was therefore considered to be non-psychoactive, though it was not assayed at other binding sites. it is toxic to the sh-sy5y cell line at high concentrations, however significantly less toxic than mdma at all concentrations tested. uwa-001 is structurally related to the diarylethylamines lefetamine (a stimulant and opioid) and the dissociative anesthetic ephenidine, which acts as a nmda receptor antagonist.